AGILE THERAPEUTICS, INC.

(AGRX)
  Report
Delayed Nasdaq  -  05/25 04:00:00 pm EDT
1.350 USD   -2.17%
05/24AGILE THERAPEUTICS INC : Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
05/23AGILE THERAPEUTICS INC : Change in Directors or Principal Officers, Regulation FD Disclosure (form 8-K)
AQ
05/23Agile Therapeutics, Inc. to Appoint Jason Butch as Principal Financial Officer
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Agile Therapeutics to Present at the Biotech Showcase and H.C. Wainwright BioConnect Virtual Conferences

01/05/2022 | 08:01am EDT

PRINCETON, N.J., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced Chairman and Chief Executive Officer Al Altomari will present at the H.C. Wainwright BioConnect Virtual Conference taking place January 10-13, 2022, and at Biotech Showcase taking place January 10-12, 2022.

Details of the presentations are as follows:

Event:H.C. Wainwright BioConnect Virtual Conference
Date:January 10-13, 2022
Time:Presentation available on-demand starting at 7:00 a.m., ET on January 10, 2022
  
Event:Biotech Showcase
Date:January 10-12, 2022
Time:Presentation available on-demand starting at 11:00 a.m., ET on January 10, 2022

The presentations will be accessible in the investor relations section of the Agile Therapeutics website here.

About Agile Therapeutics, Inc.
Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol) transdermal system, is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. For more information, please visit the company website at www.agiletherapeutics.com. The Company may occasionally disseminate material, nonpublic information on the Company’s website.

Forward-Looking Statement
Certain information contained in this press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We may in some cases use terms such as “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions, and uncertainties, including statements regarding our ongoing and planned manufacturing and commercialization of Twirla®, the potential market acceptance and uptake of Twirla, including the increasing demand for Twirla, our results of operations, revenues, financial condition, liquidity, prospects, growth and strategies, the expected benefits of our marketing and sales distribution strategies, current and future Medicare coverage for Twirla, and the development of our other potential product candidates. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including risks related to our ability to maintain regulatory approval of Twirla, the ability of Corium to produce commercial supply in quantities and quality sufficient to satisfy market demand for Twirla, our ability to successfully commercialize Twirla, the accuracy of our estimates of the potential market and the market demand for Twirla, regulatory and legislative developments in the United States and foreign countries, our ability to obtain and maintain intellectual property protection for Twirla, our strategy, business plans and focus, the effects of the COVID-19 pandemic on our operations and the operations of third parties we rely upon as well as on our potential customer base, our ability to meet or exceed the revenue thresholds necessary to permit us to access the remaining amounts available under our existing debt financing from Perceptive Advisors and the other risks set forth in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Contact: 
Matt Riley
Head of Investor Relations & Corporate Communications
mriley@agiletherapeutics.com


Primary Logo

Source: Agile Therapeutics, Inc.

2022 GlobeNewswire, Inc., source Press Releases

All news about AGILE THERAPEUTICS, INC.
05/24AGILE THERAPEUTICS INC : Change in Directors or Principal Officers, Regulation FD Disclosu..
AQ
05/23AGILE THERAPEUTICS INC : Change in Directors or Principal Officers, Regulation FD Disclosu..
AQ
05/23Agile Therapeutics, Inc. to Appoint Jason Butch as Principal Financial Officer
CI
05/23Agile Therapeutics, Inc. Announces Resignation of Dennis P. Reilly as Chief Financial O..
CI
05/17Agile Therapeutics to Present at The H.C. Wainwright Global Investment Conference
GL
05/12AGILE THERAPEUTICS : Q1 Earnings Snapshot
AQ
05/12TRANSCRIPT : Agile Therapeutics, Inc., Q1 2022 Earnings Call, May 12, 2022
CI
05/12AGILE THERAPEUTICS INC Management's Discussion and Analysis of Financial Condition and..
AQ
05/12AGILE THERAPEUTICS INC : Entry into a Material Definitive Agreement, Results of Operations..
AQ
05/12Earnings Flash (AGRX) AGILE THERAPEUTICS Posts Q1 Revenue $1.76M, vs. Street Est of $1...
MT
More news
Analyst Recommendations on AGILE THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 8,89 M - -
Net income 2022 -51,5 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,08x
Yield 2022 -
Capitalization 6,13 M 6,13 M -
Capi. / Sales 2022 0,69x
Capi. / Sales 2023 0,19x
Nbr of Employees 30
Free-Float 66,9%
Chart AGILE THERAPEUTICS, INC.
Duration : Period :
Agile Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AGILE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 1,35 $
Average target price 100,00 $
Spread / Average Target 7 307%
EPS Revisions
Managers and Directors
Alfred F. Altomari Executive Chairman
Dennis P. Reilly Chief Financial Officer & Senior Vice President
Paul Korner Chief Medical Officer
James Patrick Tursi Independent Director
John W. Hubbard Independent Director
Sector and Competitors
1st jan.Capi. (M$)
AGILE THERAPEUTICS, INC.-93.09%6
GILEAD SCIENCES, INC.-10.47%80 715
REGENERON PHARMACEUTICALS, INC.9.40%73 916
VERTEX PHARMACEUTICALS23.33%68 665
WUXI APPTEC CO., LTD.-22.98%40 017
BIONTECH SE-40.07%37 546